SABCS 2022 Conference Coverage
S

SABCS 2022 Phase 3 TAILORx Breast Cancer Trial: 21-Gene Recurrence Score and OS

By SABCS 2022 Conference Coverage FEATURING Sherry Yang
December 16, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Related Content

AUTOPLAY
30:05
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor Positive Advanced Breast Cancer Case 1: Management …

Feat. J. Abraham, R. Finn, M. Dickler
14:37
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Postive Advanced Breast Cancer Case 2: Patient with…

Feat. J. Abraham
18:34
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Positive Advanced Breast Cancer: Case 3: Treatment …

Feat. J. Abraham, R. Finn, M. Dickler
11:40
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Postive Advanced Breast Cancer Case 4: Patient with…

Feat. J. Abraham, R. Finn, M. Dickler
17:54
Heather McArthur

Modern Immune Therapy in ER, HR+/HER2-, HER2+ Breast Cancer

24:03
Holy Cross 9th Annual Winter Oncology Symposium

Early Stage Breast Cancer - Comparison of Trials of Genomic Assays -…

Feat. R. L. Mahtani
12:44
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in ER Positive Breast Cancer: CDK4/6 inhibitors, Bc…

Feat. M. Abu-Khalaf
10:12
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…

Feat. M. Abu-Khalaf
32:33
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Adjuvant Chemotherapy for HR+/HER2- Breast Cancer - How MINDACT, TAI…

Feat. L. Carey
11:57
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

HR+/HER2- Breast Cancer - Who Needs Extended Adjuvant Endocrine Ther…

Feat. L. Carey
11:07
Baltic and Eurasia Masterclass in Clinical Oncology

Advanced Breast Cancer: Endocrine Therapy as Preferred Option for HR…

Feat. O. Pagani
10:53
Baltic and Eurasia Masterclass in Clinical Oncology

Neoadjuvant Systemic Therapy for HER2 + Early Breast Cancer - Review…

Feat. A. Česas
10:00
12th ESO-EONS Masterclass in Oncology Nursing

Breast Cancer Global Epidemiology (Nurses)

Feat. O. Pagani
13:21
12th ESO-EONS Masterclass in Oncology Nursing

Neo-Adjuvant Therapy: For Who is Indicated? (Nurses)

Feat. O. Pagani
07:58
12th ESO-EONS Masterclass in Oncology Nursing

Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Diseas…

Feat. O. Pagani
13:38
2019 Scripps MD Anderson's Oncology Update

ASCO HR+/HER2 Breast Review: Practice Changing Monalessa-7 Trial Rib…

Feat. J. Mortimer
15:19
ANCO’s ASCO Highlights 2019

ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Rib…

Feat. H. Chew
16:29
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

NCCN Guidelines Update for ER+ Breast Cancer: CDK4/6 and PIK3CA Inhi…

Feat. J. Abraham, W. Gradishar
07:23
Dana-Farber Cancer Institute

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Feat. S. Tolaney
11:42
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Case: Adjuvant Systemic and Radiation Therapy Options for 68 y/o Pat…

Feat. F. Vicini, S. Modi, H. Jacene, H. Rugo